# Study of Treatment for HPV16+ ASC-US or LSIL

> **NCT03913117** · PHASE1 · RECRUITING · sponsor: **University of Alabama at Birmingham** · enrollment: 30 (estimated)

## Conditions studied

- ASC-US
- LSIL

## Interventions

- **BIOLOGICAL:** pNGVL4aCRTE6E7L2
- **BIOLOGICAL:** TA-CIN

## Key facts

- **NCT ID:** NCT03913117
- **Lead sponsor:** University of Alabama at Birmingham
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-07-10
- **Primary completion:** 2027-12
- **Final completion:** 2027-12
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2026-05-15

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03913117

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03913117, "Study of Treatment for HPV16+ ASC-US or LSIL". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT03913117. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*